- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05451810
A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) When Administered in the Outpatient Setting
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Classic Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the safety of epcoritamab in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL) who have received at least 1 prior line of systemic antilymphoma therapy including at least 1 anti-CD20 monoclonal antibody-containing therapy or R/R classic follicular lymphoma (cFL). Adverse events will be assessed.
Epcoritamab is an investigational drug being developed for the treatment of R/R DLBCL and R/R cFL. Study doctors will assess participants in a monotherapy treatment arm of epcoritamab. Participants will receive escalating doses of epcoritamab, until full dose is achieved. Approximately 184 adult participants with R/R DLBCL and R/R cFL will be enrolled in the study in approximately 80 sites in the United States of America.
Participants will receive escalating doses of subcutaneous epcoritamab, until full dose is achieved, in 28-day cycles.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: ABBVIE CALL CENTER
- Phone Number: 844-663-3742
- Email: abbvieclinicaltrials@abbvie.com
Study Locations
-
-
-
Rio Piedras, Puerto Rico, 00935
- Recruiting
- Pan American Center for Oncology Trials, LLC /ID# 254952
-
San Juan, Puerto Rico, 00918
- Recruiting
- Auxilio Mutuo Cancer Center /ID# 254953
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Recruiting
- University of Arkansas for Medical Sciences /ID# 244562
-
-
California
-
Fountain Valley, California, United States, 92708-7501
- Recruiting
- Compassionate Cancer Care Research Group - Fountain Valley /ID# 246133
-
Contact:
- Site Coordinator
- Phone Number: (714) 698-0300
-
Los Angeles, California, United States, 90095
- Recruiting
- University of California, Los Angeles /ID# 244573
-
-
Colorado
-
Boulder, Colorado, United States, 80303
- Recruiting
- Rocky Mountain Cancer Centers /ID# 247653
-
-
Connecticut
-
Stamford, Connecticut, United States, 06902-3602
- Recruiting
- Bennett Cancer Center - Stamford Hospital /ID# 244530
-
-
Florida
-
Miami Beach, Florida, United States, 33140-2948
- Recruiting
- Mount Sinai Medical Center-Miami Beach /ID# 249045
-
Pembroke Pines, Florida, United States, 33028-1023
- Recruiting
- Memorial Cancer Institute (MCI) - Memorial Hospital West /ID# 248432
-
Weston, Florida, United States, 33331-3609
- Recruiting
- Cleveland Clinic Florida /ID# 244532
-
-
Illinois
-
Chicago, Illinois, United States, 60607
- Recruiting
- University of Illinois at Chicago /ID# 245038
-
Niles, Illinois, United States, 60714
- Recruiting
- Illinois Cancer Specialists /ID# 247655
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46845-1739
- Recruiting
- Parkview Cancer Institute /ID# 244545
-
Contact:
- Site Coordinator
- Phone Number: 1-833-724-8326
-
Indianapolis, Indiana, United States, 46237
- Recruiting
- Indiana Blood & Marrow Transpl /ID# 244971
-
-
Iowa
-
Des Moines, Iowa, United States, 50314-3017
- Recruiting
- Mission Cancer and Blood /ID# 258227
-
Contact:
- Site Coordinator
- Phone Number: 515-282-2921
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70808-4375
- Recruiting
- Our Lady of the Lake Regional Medical Center /ID# 255008
-
-
Maryland
-
Bethesda, Maryland, United States, 20817
- Recruiting
- American Oncology Partners of Maryland, PA /ID# 244968
-
Contact:
- Site Coordinator
- Phone Number: 301-571-2016
-
Columbia, Maryland, United States, 21044-3128
- Recruiting
- Maryland Oncology Hematology /ID# 254192
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital /ID# 245239
-
Boston, Massachusetts, United States, 02215-5400
- Recruiting
- Beth Israel Deaconess Medical Center /ID# 248651
-
Boston, Massachusetts, United States, 02111
- Recruiting
- Tufts Medical Center /ID# 246074
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49546-7062
- Recruiting
- Cancer & Hematology Centers of Western Michigan - East /ID# 244985
-
Contact:
- Site Coordinator
- Phone Number: (616) 954-9800
-
Ypsilanti, Michigan, United States, 48197-1051
- Recruiting
- Trinity Health St. Joseph Mercy Ann Arbor /ID# 244547
-
-
Mississippi
-
Hattiesburg, Mississippi, United States, 39401
- Recruiting
- Hattiesburg Clinic /ID# 244980
-
Contact:
- Site Coordinator
- Phone Number: 601-261-1700
-
-
Missouri
-
Chesterfield, Missouri, United States, 63017
- Recruiting
- St. Luke's Hospital - Chesterfield /ID# 247815
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03756
- Recruiting
- Dartmouth-Hitchcock Medical Center /ID# 245003
-
-
New Jersey
-
Morristown, New Jersey, United States, 07960-6136
- Recruiting
- Morristown Medical Center /ID# 244973
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102-4517
- Recruiting
- University of New Mexico /ID# 252434
-
-
New York
-
New York, New York, United States, 10021
- Recruiting
- Stony Brook University Medical Center /ID# 244631
-
Port Jefferson Station, New York, United States, 11776-8060
- Recruiting
- New York Cancer and Blood Specialists /ID# 259016
-
-
North Carolina
-
Greenville, North Carolina, United States, 27834
- Recruiting
- East Carolina University Brody School of Medicine /ID# 248989
-
Winston-Salem, North Carolina, United States, 27157
- Recruiting
- Wake Forest Univ HS /ID# 245005
-
-
Ohio
-
Cincinnati, Ohio, United States, 45236-2725
- Recruiting
- Oncology Hematology Care, Inc. /ID# 246182
-
Toledo, Ohio, United States, 43623
- Recruiting
- Toledo Clinic Cancer Center /ID# 246852
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104-5418
- Recruiting
- University of Oklahoma, Stephenson Cancer Center /ID# 244568
-
-
Oregon
-
Eugene, Oregon, United States, 97401-6043
- Recruiting
- Willamette Valley Cancer Institute and Research Center /ID# 246410
-
Salem, Oregon, United States, 97301-3975
- Recruiting
- Oregon Oncology Specialists in Salem /ID# 260570
-
-
Pennsylvania
-
Allentown, Pennsylvania, United States, 18103-6202
- Recruiting
- Lehigh Valley Hospital-Cedar Crest /ID# 244984
-
Contact:
- Site Coordinator
- Phone Number: 610-402-9543
-
Hershey, Pennsylvania, United States, 17033-2360
- Recruiting
- Penn State Milton S. Hershey Medical Center /ID# 244979
-
Pittsburgh, Pennsylvania, United States, 15232
- Recruiting
- UPMC Hillman Cancer Ctr /ID# 244571
-
West Reading, Pennsylvania, United States, 19611-2143
- Recruiting
- Reading Hospital; McGlinn Cancer Institute /ID# 259181
-
-
South Carolina
-
Greenville, South Carolina, United States, 29605
- Recruiting
- Prisma Health /ID# 247654
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
- Recruiting
- The West Clinic /ID# 245004
-
Contact:
- Site Coordinator
- Phone Number: 901-683-0055
-
-
Texas
-
Austin, Texas, United States, 78705
- Recruiting
- Texas Oncology - Austin Midtown /ID# 247656
-
Dallas, Texas, United States, 75390-7208
- Recruiting
- University of Texas Southwestern Medical Center /ID# 244552
-
San Antonio, Texas, United States, 78240-5251
- Recruiting
- Texas Oncology - San Antonio Medical Center /ID# 247658
-
Tyler, Texas, United States, 75702
- Recruiting
- Texas Oncology - Northeast Texas /ID# 247657
-
-
Virginia
-
Gainesville, Virginia, United States, 20155-3257
- Recruiting
- Virginia Cancer Specialists - Gainesville /ID# 248760
-
Roanoke, Virginia, United States, 24014-2419
- Recruiting
- Blue Ridge Cancer Center /ID# 260597
-
-
Washington
-
Tacoma, Washington, United States, 98405
- Recruiting
- Northwest Medical Specialties - Tacoma /ID# 245045
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Diagnosis of Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) or R/R Classic Follicular Lymphoma (cFL), with documented CD20+ mature B-cell neoplasm according to World Health Organization (WHO) classification 2016 or WHO classification 2008 based on representative and most recent pathology report:
- Can include participants with "double-hit" or "triple-hit" DLBCL (technically classified in WHO 2016 as HGBCL, with MYC and BCL2 and/or BCL6 translocations). Note: Other double-/triple-hit lymphomas are not eligible.
- Relapsed or refractory disease and previously treated with at least 1 prior systemic anti-lymphoma therapy for DLBCL and 2 prior systemic antineoplastic therapies for cFL including at least 1 anti-CD20 monoclonal antibody-containing therapy
Has at least one target lesion defined as:
- ≥ 1 measurable nodal lesion (long axis > 1.5 cm and short axis > 1.0 cm) and/or ≥ 1 measurable extranodal lesion (long axis > 1.0 cm) on CT (or MRI) AND
- FDG PET scan demonstrating positive lesion(s) compatible with CT (or MRI) defined anatomical tumor sites.
- Must have Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2.
- Adequate organ function.
Exclusion Criteria:
- Central nervous system (CNS) involvement by lymphoma.
- Uncontrolled Human Immunodeficiency Virus (HIV) infection. HIV viral load that is undetectable and controlled with medication for at least 1 year prior to enrollment is allowed. Note: If subject has no history of HIV infection, HIV testing does not need to be conducted at screening unless it is required per local guidelines or institutional standards.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Main Cohort: Epcoritamab Diffuse Large B-Cell Lymphoma (DLBCL)
Participants with relapsed or refractory (R/R) DLBCL will receive subcutaneous (SC) epcoritamab in 28 day cycles.
|
Subcutaneous Injection (SC)
Other Names:
|
Experimental: Diversity Enriched Cohort: Epcoritamab DLBCL
Participants with R/R DLBCL will receive SC epcoritamab in 28 day cycles.
|
Subcutaneous Injection (SC)
Other Names:
|
Experimental: Main Cohort: Epcoritamab Classic Follicular Lymphoma (cFL)
Participants with R/R cFL will receive SC epcoritamab in 28 day cycles.
|
Subcutaneous Injection (SC)
Other Names:
|
Experimental: Diversity Enriched Cohort: Epcoritamab cFL
Participants with R/R cFL will receive SC epcoritamab in 28 day cycles.
|
Subcutaneous Injection (SC)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Experiencing Grade 3 or Higher Cytokine Release Syndrome (CRS) Events
Time Frame: Up to 3 Months
|
Cytokine Release Syndrome events will be graded using American Society for Transplantation and Cellular Therapy (ASTCT), with a higher grade indicating higher severity.
|
Up to 3 Months
|
Percentage of Participants Experiencing Grade 3 or Higher Immune Cell-Associated Neurotoxicity Syndrome (ICANS) Events
Time Frame: Up to 3 Months
|
ICANS events will be graded using ASTCT, with a higher grade indicating higher severity.
|
Up to 3 Months
|
Percentage of Participants Experiencing Grade 3 or Higher Neurotoxicity (Ntox) Events
Time Frame: Up to 3 Months
|
Ntox is defined as the percentage of participants who developed at least 1 Grade 3 or higher Ntox since the initiation of epcoritamab treatment.
|
Up to 3 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best Overall Response (BOR) Determined by Lugano 2014 Criteria Per Investigator Assessment
Time Frame: Up to 3 Months
|
BOR is defined as the percentage of participants who achieved best overall response of complete response (CR) or partial response (PR) determined by Lugano 2014 criteria as assessed by investigators.
|
Up to 3 Months
|
CR Determined by Lugano 2014 Criteria Per Investigator Assessment
Time Frame: Up to 3 Months
|
Complete response is defined as the percentage of participants who achieved best overall response of CR determined by Lugano 2014 criteria as assessed by investigator.
|
Up to 3 Months
|
Diversity Enriched Cohort: Incidence of Treatment-Emergent Adverse Events (TEAEs) by Severity Level
Time Frame: Up to 3 Months
|
Treatment-emergent events (TEAEs) are defined as any event that began or worsened in severity after the first dose of study drug.
|
Up to 3 Months
|
Diversity Enriched Cohort: Severity of TEAEs by Severity Level
Time Frame: Up to 3 Months
|
Treatment-emergent events (TEAEs) are defined as any event that began or worsened in severity after the first dose of study drug.
|
Up to 3 Months
|
Diversity Enriched Cohort: Incidence of Serious Adverse Events (SAEs) by Severity Level
Time Frame: Up to 3 Months
|
A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.
|
Up to 3 Months
|
Diversity Enriched Cohort: Severity of SAEs by Severity Level
Time Frame: Up to 3 Months
|
A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.
|
Up to 3 Months
|
Diversity Enriched Cohort: Median Time to Onset of CRS of Grade 3 or Higher
Time Frame: Up to 3 Months
|
Median time to onset of CRS of Grade 3 or higher.
|
Up to 3 Months
|
Diversity Enriched Cohort: Median Time to Resolution of CRS of Grade 3 or Higher
Time Frame: Up to 3 Months
|
Median time to resolution of CRS of Grade 3 or higher.
|
Up to 3 Months
|
Diversity Enriched Cohort: Median Time to Onset of ICANS of Grade 3 or Higher
Time Frame: Up to 3 Months
|
Median time to onset of ICANS of Grade 3 or higher.
|
Up to 3 Months
|
Diversity Enriched Cohort: Median Time to Resolution of ICANS of Grade 3 or Higher
Time Frame: Up to 3 Months
|
Median time to resolution of ICANS of Grade 3 or higher.
|
Up to 3 Months
|
Diversity Enriched Cohort: Median Time to Onset of Ntox of Grade 3 or Higher
Time Frame: Up to 3 Months
|
Median time to onset of Ntox of Grade 3 or higher.
|
Up to 3 Months
|
Diversity Enriched Cohort: Median Time to Resolution of Ntox of Grade 3 or Higher
Time Frame: Up to 3 Months
|
Median time to resolution of Ntox of Grade 3 or higher.
|
Up to 3 Months
|
Diversity Enriched Cohort: Percentage of Participants Experiencing Any Adverse Events (AE)s
Time Frame: Up to 3 Months
|
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.
|
Up to 3 Months
|
Diversity Enriched Cohort: Percentage of Participants Receiving Various Interventions for the Management of CRS After the First Full Dose of Epcoritamab
Time Frame: Up to 3 Months
|
Percentage of participants receiving various interventions for the management of CRS after the first full dose of epcoritamab.
|
Up to 3 Months
|
Diversity Enriched Cohort: Percentage of Participants Receiving Various Interventions for the Management of ICANS After the First Full Dose of Epcoritamab
Time Frame: Up to 3 Months
|
Percentage of participants receiving various interventions for the management of ICANS after the first full dose of epcoritamab.
|
Up to 3 Months
|
Diversity Enriched Cohort: Percentage of Participants Receiving Various Interventions for the Management of Ntox After the First Full Dose of Epcoritamab
Time Frame: Up to 3 Months
|
Percentage of participants receiving various interventions for the management of Ntox after the first full dose of epcoritamab.
|
Up to 3 Months
|
Diversity Enriched Cohort: Duration of response (DOR)
Time Frame: Up to 3 Months
|
Duration of response is defined for participants who achieved BOR of CR or PR ('responders'), as the time in months from initial CR/PR to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
|
Up to 3 Months
|
Diversity Enriched Cohort: Progression-free survival (PFS)
Time Frame: Up to 3 Months
|
Progression-free survival is defined as the time in months from the first dose of study drug to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
|
Up to 3 Months
|
Diversity Enriched Cohort: Overall survival (OS)
Time Frame: Up to 3 Months
|
Overall survival is defined for as the time in months from first dose of epcoritamab to death from any cause.
|
Up to 3 Months
|
Diversity Enriched Cohort: Time-to-response (TTR)
Time Frame: Up to 3 Months
|
Time to response is defined for participants who achieved BOR of CR or PR ('responders') determined by Lugano 2014 criteria as assessed by investigator, as the time in months from first dose of study drug to initial CR/PR.
|
Up to 3 Months
|
Diversity Enriched Cohort: Duration of CR (DOCR)
Time Frame: Up to 3 Months
|
The duration of complete response is defined for participants who achieved BOR of CR (Complete Responders), as the duration from the first CR response to the earliest date of disease progression determined per Lugano 2014 criteria, as assessed by the investigator, or death, whichever occurs first.
|
Up to 3 Months
|
Diversity Enriched Cohort: Time to Next Treatment
Time Frame: Up to 3 Months
|
Time to next treatment is defined as the time from the date of the first dose of study drug to the start of new non-protocol-specified treatment or death from any cause.
|
Up to 3 Months
|
Collaborators and Investigators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- M23-362
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diffuse Large B-Cell Lymphoma
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); AmgenActive, not recruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive | Stage I Diffuse Large B-Cell Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell LymphomaUnited States
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
University Hospital Southampton NHS Foundation...Hoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited Kingdom
-
National Cancer Institute (NCI)WithdrawnDiffuse, Large B-cell Lymphoma | Lymphoma, Diffuse Large-Cell | Lymphoma, Diffuse Large-Cell B-cell | Large-Cell Lymphoma, Diffuse
-
Dana-Farber Cancer InstituteBayer; AbbVieActive, not recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
Autolus LimitedCompletedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell LymphomaUnited States, United Kingdom
-
Herlev HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsCompletedDiffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Cell of Origin
-
UNC Lineberger Comprehensive Cancer CenterCephalonCompletedLymphoma | Diffuse Large B-Cell Lymphoma | Lymphoma, Diffuse Large-Cell | Diffuse Large-Cell LymphomaUnited States
Clinical Trials on Epcoritamab
-
AbbVieGenmabRecruitingNon-hodgkin LymphomaUnited States, Australia, France, Israel, Korea, Republic of, Spain, Taiwan, Japan, Italy, Belgium, Germany, Canada, Turkey, Czechia
-
GenmabAbbVieActive, not recruitingSmall Lymphocytic Lymphoma (SLL) | DLBCL | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | MCL | Marginal Zone Lymphoma (MZL) | High-grade B-cell Lymphoma (HGBCL) | FLKorea, Republic of, United States, Australia, Singapore, Netherlands, Sweden, France, Finland, United Kingdom, Spain, Germany, Denmark, Italy, Poland, Canada
-
GenmabAbbVieApproved for marketingPrimary Mediastinal Large B-cell Lymphoma (PMBCL) | Large B-cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-cell Lymphoma (HGBCL) | Grade 3B Follicular Lymphoma
-
Stichting Hemato-Oncologie voor Volwassenen NederlandGerman CLL Study Group; Nordic CLL Study GroupRecruitingCLL/SLLNetherlands, Denmark, Belgium, Germany
-
GenmabAbbVieActive, not recruitingDiffuse Large B-cell LymphomaKorea, Republic of, Spain, Taiwan, Belgium, France, Israel, United Kingdom, China, United States, Netherlands, Japan, Sweden, Turkey, Australia, Singapore, Germany, Denmark, Poland, Italy, Hungary, Austria, Russian Federation, Norway, Canad... and more
-
GenmabAbbVieTerminatedFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-cell Lymphoma | Small Lymphocytic Lymphoma | High-grade B-cell Lymphoma | Primary Mediastinal Large B-cell LymphomaUnited States, Spain, Netherlands, Belgium, France, Denmark
-
Australasian Leukaemia and Lymphoma GroupNot yet recruitingHigh-grade B-cell Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | DLBCL, Nos Genetic Subtypes | High Grade B-Cell Lymphoma, Not Otherwise Specified | Follicular Large Cell Lymphoma, Relapsed | Follicular Large Cell Lymphoma
-
Reid Merryman, MDAbbVie; GenmabRecruitingFollicular Lymphoma | Low Grade Non-Hodgkin's Lymphoma, AdultUnited States
-
Dipenkumar ModiGenmabRecruitingRelapsed Cancer | Refractory Cancer | Large Cell Lymphoma, DiffuseUnited States